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INTRODUCTION
High-dose chemo- or chemoradiotherapy followed by allogeneic hematopoietic
cell transplantation (HCT) has been recognized as an effective therapy for a
number of hematologic malignancies with tumor cells resistant to conventional
doses of chemotherapy (1). The aims of the high-dose conditioning are (i) to
abolish host immune responsiveness prior to transplantation to avoid graft rejec-
tion and (ii) to deliver doses of cytotoxic anticancer agents beyond the range that is
toxic to the bone marrow cells, thereby potentially increasing antitumor efficacy (1).
The curative potential of allogeneic HCT is not only due to the high-dose che-
moradiotherapy but also due to immune-mediated graft-versus-tumor (GVT)
effects (2–4).
The existence of a GVT effect was first suggested by Barnes et al. in 1956 (5).
They observed that mice receiving syngeneic HCT and injection of congenic
leukemic cells after total body irradiation (TBI) almost uniformly died from
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leukemia, whereas a number of mice receiving histoincompatible marrow were
cured of leukemia but eventually died from the graft-versus-host disease
(GVHD). The authors suggested that a reaction of the donor spleen cells might
kill cancer cells. This hypothesis was evinced two decades later in humans by
studies reporting reduced leukemic relapse rates in allografted patients who
developed GVHD compared with those who did not (2,3). The GVT effect was
further demonstrated by other investigators who observed increased risks of
relapse in patients given T-cell-depleted grafts and in recipients of syngeneic
transplants (3).
Those observations led several groups of investigators to investigate the
curative potential of donor lymphocytes infusions (DLI) in patients who had
relapsed after allogeneic HCT (4). Two large multicenter studies, one from the
European Group for Blood and Marrow Transplantation (EBMT) (4) and the
other from North America (6), have analyzed the efficacy of DLI in more than
400 patients (Table 1). DLI induced complete remissions in more than 60% of
patients with chronic myeloid leukemia and 10% to 40% of patients with other
hematologic malignancies. Typically, achievement of complete remissions
required several weeks. For example, an average time of four to six months was
required before molecular remission was achieved in patients with relapsed
chronic myeloid leukemia (4). While 50% of patients without acute GVHD
showed tumor regression, this increased to 75% and 85% in patients with grade I
or grades II to IV acute GVHD, respectively (4). Similarly, chronic GVHD was
associated with disease responses (4,6). DLI have been given without any other
treatment in patients with indolent disease such as chronic myeloid leukemia in
chronic phase, while chemotherapy has been given before DLI in a number of
Table 1 Results of Donor Lymphocyte Infusions as Treatment of Relapse After HLA-
Matched HCT Following Myeloablative Conditioning
North America (6)
Complete response/
evaluable patients (%)
EBMT (4)
Complete response/
evaluable patients (%)
Chronic myeloid leukemia
Cytogenetic/molecular relapse 3/3 (100) 40/50 (80)
Hematologic relapse 25/34 (74) 88/114 (77)
Accelerated phase/blast crisis 5/18 (28) 13/36 (36)
Acute myeloid leukemia/
myelodysplastic syndrome/
polycythemia vera
8/44 (18) 16/59 (27)
Acute lymphoblastic leukemia 2/11 (18) 3/20 (15)
Multiple myeloma 2/4 (50) 5/17 (29)
Non-Hodgkin’s lymphoma 0/6 (0) —
Abbreviation: EBMT, European Group for Blood and Marrow Transplantation.
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patients with more aggressive diseases. Figure 1 shows overall survival in 48
patients given DLI for progressive disease/relapse after nonmyeloablative con-
ditioning (7).
Because of regimen-related toxicities, the use of Q1high-dose myeloablative
conditionings has been restricted to younger and medically fit patients. This is
unfortunate, given that the median age at diagnosis of patients with acute and
chronic myeloid leukemias, chronic lymphocytic leukemia, non-Hodgkin’s
lymphomas (NHLs), myelodysplastic syndromes, and multiple myeloma ranges
from 65 to 70 years (1). In 1971, Santos et al. reported that conditioning with
cyclophosphamide alone, although nonmyeloablative enabled sustained
engraftment of transplanted allogeneic hematopoietic cells in patients with
advanced leukemia (8). Unfortunately, tumor cells were not completely eradi-
cated, and all patients eventually relapsed. While cyclophosphamide became the
conditioning regimen of choice for patients with aplastic anemia (1), it was
abandoned as the sole conditioning regimen in patients with hematologic
malignancies. In 1974, Graw et al. reported a few cures in patients with acute
leukemia given allogeneic marrows after a reduced-intensity (9) conditioning
regimen combining BCNU, cytarabine, cyclophosphamide, and thioguanine (10).
The growing evidence of the power of GVT effects, as demonstrated by the
efficacy of DLI, incited several groups of investigators to develop new reduced-
intensity (11–14) or truly nonmyeloablative conditioning regimens (15–17)
allowing older patients and those with comorbidities to benefit from GVT effects
(Table 2).
Figure 1 Diagnosis and survival after DLI given for progressive disease/relapse after
nonmyeloablative HCT. Kaplan–Meier plots of survival after DLI depending on diag-
noses. Survival estimates at one year were 61% for B-cell malignancies, 51% for chronic
leukemia, 50% for solid tumors, 13% for acute leukemia, and again 13% for myelodys-
plastic syndrome, respectively. Source: From Ref. 7. Q5
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NONMYELOABLATIVE OR REDUCED-INTENSITY REGIMENS
Many of the reduced-intensity conditioning regimens do not meet criteria of
nonmyeloablative conditioning as first proposed by Champlin et al., which
include (i) no eradication of host hematopoiesis, (ii) prompt hematologic
revovery (<4 weeks) without transplant, and (iii) presence of mixed chimerism
upon engraftment (18,19). Most reduced-intensity conditioning regimens com-
bine modest dose of highly immunosuppressive purine analogs (fludarabine,
cladribine, or pentostatin) given to overcome host-versus-graft reactions, with
reasonably high-dose of alkylating agents, usually busulfan or melphalan, given
to supplement the GVT effects in the task of tumor eradication. Conversely,
nonmyeloablative conditioning regimens usually combine two highly immuno-
suppressive agents together (low-dose TBI, fludarabine, or cyclophosphamide)
to overcome host-versus-graft reactions to allow engraftment and tumor eradi-
cation via GVT effects (16,20). Although the division of what constitutes a
nonmyeloablative versus reduced-intensity conditioning regimen is somewhat
arbitrary, the distinction might be important, given that nonmyeloablative con-
ditioning has been associated with a lower degree of donor engraftment,
decreased risk of nonrelapse mortality, and perhaps higher risk of relapse in
comparison with reduced-intensity regimens (21).
NONMYELOABLATIVE CONDITIONING WITH 2 GY TBI
AND FLUDARABINE
On the basis of preclinical studies in a canine model (22), we developed a
nonmyeloablative conditioning regimen for allogeneic HCT consisting of 2 Gy
TBI given on day 0, with postgrafting immunosuppression combining myco-
phenolate mofetil (MMF) and cyclosporin (CSP) (16). Nine of the first
44 patients (20%, including four of eight patients with chronic myeloid leuke-
mia) given this regimen had nonfatal graft rejections (16,23). In order to reduce
the risk of graft rejection, fludarabine 30 mg/m2/day  3 days was added to the
2 Gy TBI, and the rejection rate decreased to 3% (24). The same nonmyeloablative
regimen combining fludarabine and 2 Gy TBI was used to condition patients
with 10/10-human leukocyte antigen Q2(HLA)-matched unrelated donors (25).
Sustained engraftment was observed in 60 of 71 (85%) peripheral blood stem
cells (PBSC) recipients and in 10 of 18 (56%) marrow recipients. On the basis of
this observation, all subsequent unrelated recipients were given PBSC grafts.
Analysis of the first 451 patients with hematologic malignancies transplanted in
a multicenter international consortium is shown in Table 1 (24). Median patient
age was 55 (range, 5–74) years, and median follow-up was 696 (range, 82–1795)
days. All patients were deemed ineligible for myeloablative conditioning because
of age and/or comorbidities. Diagnoses included multiple myeloma (n ¼ 114),
myelodysplastic syndromes or myeloproliferative disorders (n ¼ 82), NHLs
(n ¼ 79), acute myeloid leukemia (n ¼ 59), chronic lymphocytic leukemia
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(n ¼ 44), chronic myeloid leukemia (n ¼ 37), Hodgkin’s disease (n ¼ 26), and
acute lymphoblastic leukemia (n ¼ 10). Three hundred and thirty-two patients
had measurable disease at transplantation, and 56.5% achieved complete (49%)
or partial (7.5%) remissions. The incidences of nonrelapse mortality at 100 days
and two years were 7% and 22%, respectively. Main causes of nonrelapse
mortality were GVHD and infections. The two-year probabilities of overall and
progression-free survivals were 51% and 37%, respectively.
KINETICS OF DONOR ENGRAFTMENT AFTER
NONMYELOABLATIVE CONDITIONING
The engraftment kinetics after nonmyeloablative conditioning regimen were first
analyzed by Childs et al. (17). The authors studied chimerism (i.e., proportion of
hematopoietic cells of donor origin) evolution in 15 patients conditioned with
fludarabine (125 mg/m2) and cyclophosphamide (120 mg/kg). The patterns of
engraftment varied between patients, but most often, full donor chimerism was
achieved earlier among T-cells than among granulocytes, and achievement of
full donor T-cell chimerism preceded GVHD and antitumor responses. Con-
versely, Ueno et al. studied chimerism evolution in 23 patients with metastatic
tumors transplanted after conditioning with fludarabine (125–150 mg/m2) and
melphalan (140 mg/m2) (26). All patients had full donor T-cell and granulocyte
chimerisms by day 30 after HCT.
We analyzed the kinetics of donor engraftment in various peripheral
blood hematopoietic subpopulations from 120 patients conditioned with 2 Gy
TBI þ/ fludarabine and postgrafting immunosuppression with MMF and
CSP (27). On day 14 post transplant, the highest degree of donor chimerism
was seen in the NK cells followed by T-cells, monocytes, and granulocytes
(Fig. 2A). By day 28, donor granulocyte chimerism had surpassed those in the
remaining cell populations. PBSC recipients had higher degrees of donor
T-cell chimerism than recipients of marrow, while greater intensity of therapy
before HCT was associated with higher degrees of donor chimerisms. Day-14
donor chimerism levels less than 50% among T-cells (p ¼ 0.0007) and NK
cells (p ¼ 0.003) predicted graft rejection (Fig. 2B). High donor chimerism
levels on day 14 among T-cells were associated with increased risks of grades II
to IV acute GVHD (p ¼ 0.02), while high donor T-cell (p ¼ 0.002) and NK cell
(p ¼ 0.002) chimerism levels from days 14 to 42 were associated with decreased
risks of relapse. In addition, high levels of donor NK cell chimerism early after
HCT correlated with better progression-free survival (p ¼ 0.02) and a trend for
better overall survival (p ¼ 0.09).
These observations suggest that assessing donor chimerism levels among
T-cells and NK cells might help identify patients at risk for graft rejection, acute
GVHD, and relapse, and thereby allow early interventions with DLI and/or
immunosuppressive drugs (7,28).
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GVHD AND GVT EFFECTS AFTER NONMYELOABLATIVE
CONDITIONING
GVHD remains a major cause of morbidity and mortality after nonmyeloablative
or reduced-intensity conditioning (16,25). Mielcarek et al. compared GVHD in
52 patients given myeloablative conditioning with that among 44 patients given
nonmyeloablative conditioning (29). Recipients in both groups were age
matched, with median ages of 54 years in the myeloablative and 56 years in the
nonmyeloablative groups. Grafts were from either related or unrelated donors
who were serologically matched for HLA-A, -B, and -C and allele level matched for
HLA-DRB1 and -DQB1. Postgrafting immunosuppression consisted of metho-
trexate (MTX) plus CSP (n ¼ 45) or MMF plus CSP (n ¼ 7) in myeloablative
Figure 2 (A) Engraftment kinetics after nonmyeloablative conditioning in 108 patients
who achieved sustained engraftment. (B) Cumulative incidence of graft rejection
according to day-14 T-cell chimerism. Source: From Ref. 27.
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recipients, versus MMF plus CSP in all nonmyeloablative recipients. The cumu-
lative incidences of grades II to IV acute GVHD were 85% in myeloablative
recipients versus 64% in nonmyeloablative recipients (p¼ 0.001), but there were no
differences in the cumulative incidences of extensive chronic GVHD (71% vs. 73%,
respectively). The 15-month cumulative incidences of death with manifestations of
GVHD under treatment were 35% and 24% in myeloablative and nonmyeloablative
recipients, respectively (NS).
Although there is a close relationship between GVHD and GVT responses
observed after myeloablative HCT (2–4,6), whether some degree of clinical
GVHD was required for accomplishing remissions after nonmyeloablative
conditioning was less clear. In order to address this question, we analyzed the
impact of either acute or chronic GVHD on HCT outcomes in 322 patients with
hematologic malignancies given grafts from HLA-matched related (n ¼ 192) or
unrelated (n ¼ 130) donors following conditioning with 2 Gy TBI with or
without fludarabine (90 mg/m2) (20). Two hundred and twenty-one patients had
measurable malignant disease at the time of transplantation, and 126 of them
(57%) achieved complete (n ¼ 98) or partial (n ¼ 28) remissions 27 to 963 days
(median, 176 days) after HCT. Extensive chronic GVHD was suggestively
associated with a higher probability of achieving complete remissions (HR 1.7,
p ¼ 0.07), but no associations between acute GVHD and achievement of com-
plete remissions were seen. Grades II and III to IV acute GVHD did not decrease
the risks of progression/relapse but were associated with an increased risk of
nonrelapse mortality and decreased progression-free survival. In contrast,
extensive chronic GVHD was associated with decreased risk of progression/
relapse (HR 0.4, p ¼ 0.006) and better progression-free survival (HR 0.5,
p ¼ 0.003) (Fig. 3). The beneficial impact of chronic GVHD on relapse was seen
in all disease groups but was strongest in the group of patients with acute
myeloid leukemia or myelodysplastic syndrome (HR 0.2, p ¼ 0.0009).
Similarly, a number of other recent reports have shown a negative impact
of grades II to IV acute GVHD (30,31) but a beneficial impact of chronic GVHD
(31,32) on HCT outcomes in patients given HCT after reduced-intensity or
nonmyeloablative conditioning.
Some reduced-intensity conditioning regimens have used in vivo T-cell
depletion of the grafts [with either antithymocyte globulin (ATG) or alemtuzu-
mab] to decrease the incidence of GVHD. While these strategies achieved their
goal (11,13), increased incidences of both infections and disease relapses were
observed, resulting in comparable progression-free survival.
TOXICITIES AFTER MYELOABLATIVE OR
NONMYELOABLATIVE CONDITIONING
A number of retrospective studies have compared incidences of toxicity and
infection after nonmyeloablative versus myeloablative conditioning (Table 3)
(33–37). Nonmyeloablative conditioning was associated with decreased
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transfusion requirements (33), decreased incidence of idiopathic pneumonia
syndrome (IPS) (34), decreased incidence of sinusoidal obstruction syndrome
(SOS) (35), decreased incidence of acute renal failure (38), and decreased
incidence of bacterial and cytomegalovirus (CMV) Q3infections early after HCT
(36,37). However, overall CMV reactivations and fungal infections were simi-
larly frequent after nonmyeloablative and myeloablative conditioning (36,37).
Sorror et al. analyzed transplantation-related toxicities (graded according to
the National Cancer Institute common toxicity criteria) following HLA-matched
unrelated HCT in 134 concurrent patients given either nonmyeloablative (n ¼ 60)
or myeloablative (n ¼ 74) conditioning (39). Additionally, the effects of pre-
transplant comorbidities [graded according to the Charlson Comorbidity Index
(CCI) score] on outcome were investigated. Lower numbers of gastrointestinal
(p < 0.0001), hepatic (p ¼ 0.005), hematologic (p < 0.0001), infection-related
(p ¼ 0.02), and hemorrhagic (p ¼ 0.02) grades III to IV toxicities were seen in
nonmyeloablative compared with myeloablative recipients, whereas incidences of
cardiovascular, metabolic, pulmonary, and renal toxicities were not statistically
significantly different between the two groups. The one-year nonrelapse mortality
was 32% in patients given myeloablative conditioning compared with 20% in
patients given nonmyeloablative conditioning. In multivariate analyses adjusting
for disease risk, age, and CCI score at HCT, myeloablative conditioning was
Figure 3 Semilandmark plots illustrating progression-free survival among patients with
and without extensive chronic GVHD (20). For patients diagnosed with extensive chronic
GVHD, survival is plotted as a function of time since onset of GVHD. For patients free of
disease progression and without a diagnosis of extensive chronic GVHD at day 135 (the
median day of onset for those with extensive chronic GVHD), survival is plotted as a
function of time since day 135. For this group the survival is the conditional survival
among patients remaining without a diagnosis of extensive chronic GVHD. Abbreviation:
GVHD, graft-versus-host disease. Source: From Ref. 20.
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associated with increased risks of grade IV toxicities (HR 9.4, p ¼ 0.0001) and
higher one-year nonrelapse mortality (HR 3.0, p ¼ 0.04). Interestingly, higher
pretransplant CCI scores predicted for increased mortality. Comparable results
were observed by Diaconescu et al. in patients given grafts from HLA-identical
sibling donors (40).
Table 3 Toxicity After Nonmyeloablative (Consisting of 2 Gy Total Body Irradiation
with or Without 90 mg/m2 Fludarabine) Vs. Myeloablative Conditioning Regimens
Toxicity (Refs.) Nonmyeloablative Myeloablative p value
Hematological Toxicity (transfusion requirements) (33)
Median units red cells 2 (0–50) 6 (0–34) p ¼ 0.0002
Median units platelets 0 (0–214) 24 (4–358) p < 0.0001
Pulmonary Toxicity (34)
120-day CI of IPS 2.2% 8.4% p ¼ 0.003
Hepatic Toxicity (35,40)
200-day CI of
hyperbilirubinemiaa
26% 48% ND
100-day CI of sinusoidal
obstructive syndrome
0% 18% ND
Renal toxicity (38)
100-day CI of grades II–III
acute renal failure
47% 73% p < 0.0001
100-day CI of dialysis 3% 12% p < 0.0001
Infections (36,37)
30-day CI of bacterial
infection
9% 27% p ¼ 0.01
100-day CI of bacterial
infection
27% 41% p ¼ 0.07
1-yr CI of aspergillosis 14% 10% p ¼ 0.30
100-day CI of CMV disease 6% 19% p ¼ 0.06
1-yr CI of CMV disease 24% 25% p ¼ 0.87
GVHD (29)
100-day CI of grades II–IV
acute GVHD
Matched siblings 62% 77% p ¼ 0.02
Matched unrelated donors 65% 95% p ¼ 0.01
CI of extensive chronic
GVHD
Matched siblings 77% 74% p ¼ 0.37
Matched unrelated donors 68% 69% p ¼ 0.37
Mortality from GVHD 24% 35% p ¼ 0.07
a4 mg/dL.
Abbreviations: CI, cumulative incidence; IPS, idiopathic pneumonia syndrome; ARF, acute renal
failure; CMV, cytomegalovirus; GVHD, graft-versus-host disease.
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RELAPSE AND SURVIVAL AFTER MYELOABLATIVE
OR NONMYELOABLATIVE CONDITIONING
It has remained difficult to compare relapse risk and survival after myeloablative
versus nonmyeloablative recipients, given the short follow-up (and relatively low
number) of patients given HCT after nonmyeloablative conditioning so far and
the fact that nonmyeloablative recipients were generally older and had more
comorbidities than patients given myeloablative conditioning. Two randomized
studies in the early 1990s demonstrated lower risk of relapse, increased non-
relapse mortality, and similar survival in patients treated with cyclophosphamide
and 15.5 Gy versus 12 Gy TBI followed by HLA-identical sibling HCT, dem-
onstrating that dose intensity does matter for both toxicity and antitumor efficacy
(41,42).
Alyea et al. performed a retrospective analysis of 152 patients (>50 years
old) with hematologic malignancies undergoing HCT after myeloablative
[mainly cyclophosphamide (3.6 g/m2) and TBI (14 Gy)] or reduced-intensity
conditioning combining fludarabine (120 mg/m2) and intravenous busulfan
(3.2 mg/kg) (43). Patients given nonmyeloablative conditioning were more likely
to receive grafts from unrelated donors (58% vs. 36%, p ¼ 0.009), to have
received a prior HCT (25% vs. 4%, p < 0.0001), and to have active disease at the
time of transplantation (85% vs. 59%, p < 0.001). With a median follow-up of
18 months, the cumulative incidences of relapse and nonrelapse mortality were
46% and 32% in the reduced-intensity conditioning group, versus 30% and 50%,
respectively, in the myeloablative group. Two-year overall survival was perhaps
superior in the nonmyeloablative group (39% vs. 29%; p ¼ 0.056).
RESULTS IN SPECIFIC DISEASES
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Hegenbart et al. analyzed outcome of 122 patients with acute myeloid leukemia
ineligible for conventional HCT given allogeneic grafts after 2 Gy TBI with or
without added fludarabine (90 mg/m2), and postgrafting immunosuppression
combining MMF and CSP (44). Two-year probabilities of overall survival were
51% for patients transplanted in first complete remission (n ¼ 51), 61% for those
transplanted in second remission (n ¼ 39), and 28% for those transplanted
beyond second remission (n ¼ 32) (Fig. 4). High cytogenetic risks predicted for
decreased overall survival (HR 2.4, p ¼ 0.008).
Using a genetic randomization through a ‘‘donor’’ versus ‘‘no donor’’
comparison, Mohty et al. investigated whether allogeneic HCT after conditioning
with fludarabine (180 mg/m2), busulfan (8 mg/kg), and ATG increased survival in
adults (median age 52 years) with newly diagnosed high-risk acute myeloid leu-
kemia in first complete remission ineligible for conventional HCT (45). Ninety-
five patients were retrospectively analyzed; 35 had an HLA-identical sibling donor
(donor group), while 60 had no related HLA-matched donor (no donor group).
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Twenty-five of thirty-five patients included in the donor group (71%) received
allogeneic HCT. The 10 remaining patients with an identified donor did not
receive allogeneic HCT because of patient or donor refusal (n ¼ 6), early relapse
(n ¼ 2), or psychiatric disorders appearing before HCT (n ¼ 2). In an intention to
Figure 4 Example of GVT response in a patient with mantle cell lymphoma relapsing
after high-dose radiolabeled antibodies with autologous peripheral blood stem cell sup-
port. (A) Pretransplantation CT scan image (day 27) through the upper pelvis demon-
strating an 8-cm by 7-cm mass that extended through 12 0.5-cm cuts. (B) CT scan image
through the same region demonstrating complete resolution of the mass on day þ74 after
nonmyeloablative transplantation from a matched unrelated donor. The patient remains in
remission 30 months after transplantation with no evidence of GVHD. Abbreviations:
GVT, graft-versus-tumor; CT, computed tomography; GVHD, graft-versus-host disease.
Source: From Ref. 50.
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treat analysis, the four-year probability of progression-free survivals was 54% in
the donor group versus 30% in the nondonor group (p ¼ 0.01).
Ho et al. analyzed data from 62 patients with myelodysplastic syndrome
given allografts from related (n ¼ 24) or unrelated (n ¼ 38) donors after reduced-
intensity conditioning with fludarabine (150 mg/m2), oral busulfan (8 mg/kg),
and alemtuzumab (100 mg total dose) (46). Postgrafting immunosuppression
consisted of CSP alone. Median patient age at HCT was 56 years for patients
given grafts from siblings and 52 years for patients given grafts from unrelated
donors. Sixteen patients had refractory anemia, 19 refractory anemia with blast
excess, 23 refractory anemia with blast excess in transformation, and 4 chronic
myelomonocytic leukemia. The one-year probabilities of nonrelapse mortality,
overall survival, and progression-free survival were 5%, 73%, and 61%,
respectively, for patients given grafts from related donors versus 21%, 71%, and
59%, respectively, for patients given grafts from unrelated donors.
Chronic Myeloid Leukemia
Or et al. reported data from 24 patients (median age 35 years) with chronic
myeloid leukemia in first chronic phase given HLA-matched related (n ¼ 19) or
unrelated (n ¼ 5) grafts after reduced-intensity conditioning combining fludar-
abine (180 mg/m2), busulfan (8 mg/kg), and ATG (11). Day-100 mortality was
0%, but three patients died as a consequence of GVHD 116, 499, and 726 days
after HCT. The five-year probability of progression-free survival was 85%, with
all 21 survivors having negative reverse transcriptase-polymerase chain reaction
(RT-PCR) for Bcr-Abl.
Kerbauy et al. analyzed data from 24 patients (median age 58 years) with
chronic myeloid leukemia in first chronic phase (n ¼ 14) or beyond (n ¼ 10)
given PBSC from HLA-matched related donors after conditioning with 2 Gy TBI
with (n ¼ 16) or without (n ¼ 8) fludarabine (23). Four of eight patients not
given fludarabine experienced nonfatal graft rejection and recurrence of chronic
myeloid leukemia, while the 20 remaining patients achieved sustained engraft-
ment. The two-year overall survival rate was 70% for patients transplanted in
first chronic phase, and 56% for those with more advanced disease. Nine of ten
patients transplanted in first chronic phase after conditioning with 2 Gy TBI with
fludarabine achieved molecular remissions 3 to 24 months after HCT.
In contrast to what was observed in patients given grafts from HLA-
matched sibling donors, a high rate of graft rejection among chronic myeloid
leukemia patients receiving grafts from unrelated donors after nonmyeloablative
or reduced-intensity conditioning has been reported. We observed graft rejection
in 9 of 21 patients given unrelated grafts for chronic myeloid leukemia after 2 Gy
TBI and fludarabine (47). Graft rejections were nonfatal in all cases and fol-
lowed by autologous reconstitution with persistence or recurrence of chronic
myeloid leukemia. Seven of eleven patients with sustained engraftment,
including all five patients in first chronic phase were alive in complete
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cytogenetic remissions 118–1205 (median 867) days after HCT. Hallemeier et al.
observed graft failure in 5 of 22 evaluable patients given unrelated grafts after
conditioning with 5.5 Gy TBI and cyclophosphamide (120 mg/kg) (14). Further
efforts for reducing the risk of graft rejection in patients with chronic myeloid
leukemia given unrelated HCT are directed at increasing the degree of pre-
transplant immunosuppression.
Lymphoma and Chronic Lymphocytic Leukemia
Khouri et al. reported results in 20 patients (median age 51 years) with low-grade
NHL given grafts from siblings after conditioning with fludarabine (90–125 mg/m2)
and cyclophosphamide (2000–2250 mg/m2), with or without added rituximab
(15). Postgrafting immunosuppression consisted of tacrolimus and MTX. After a
median follow-up of 21 months, the two-year current probability of disease-free
survival was 84%. The same authors evaluated the efficacy of nonmyeloablative
HCT in 20 patients with NHL recurrence after autologous HCT (48). Ten
patients achieved complete remission with salvage chemotherapy before non-
ablative HCT, eight had a partial response, and two had stable disease. One
patient died at 10.5 months from a fungal infection. The three-year progression-
free survival was 95%.
Robinson et al. analyzed data from 188 patients (median age 40 years) with
lymphoma [low-grade NHL (n ¼ 52), high-grade NHL (n ¼ 62), mantle cell
lymphoma (n ¼ 22), or Hodgkin’s disease (n ¼ 52)] given HCT after various
reduced-intensity or nonmyeloablative conditioning in EBMT-affiliated centers
(49). The one-year probabilities of nonrelapse mortality were 39% and 22% in
patients older or younger than 50 years, respectively (p ¼ 0.03). The two-
year probabilities of overall and progression-free survival were 65% and 54% for
patients with low-grade NHL, 47% and 13% for patients with high-grade NHL,
13% and 0% for patients with mantle cell lymphoma, and 56% and 42%,
respectively, for patients with Hodgkin’s disease. Chemosensitive disease at
HCT was associated with better overall (RR, 2.4; p ¼ 0.002) and progression-
free (RR, 2.3; p ¼ 0.007) survivals in multivariate analyses.
Morris et al. reported results of 88 patients with NHL given allogeneic
HCT after conditioning with fludarabine (150 mg/m2), melphalan (140 mg/m2),
and alemtuzumab (100 mg) (13). Sixty-five patients received PBSC from HLA-
identical siblings, while 23 received bone marrow from matched unrelated
donors. GVHD prophylaxis consisted of CSP alone. Before DLI, grades III to IV
acute GVHD were seen in four patients, but two additional patients developed
grade IV acute GVHD after DLI. The actuarial three-year probability of current
progression-free survival was 65% for patients with low-grade lymphoma
(n ¼ 41), 50% for patients with mantle cell lymphoma (n ¼ 10), and 34% for
patients with high-grade lymphoma (n ¼ 37) (Table 2).
Maris et al. analyzed outcomes of 33 patients with relapsed or refractory
mantle cell lymphoma who underwent allogeneic HCT from related (n ¼ 16) or
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unrelated (n ¼ 17) donors after 2 Gy TBI and fludarabine (90 mg/m2) (50). The
overall response rate in the 20 patients with measurable disease at the time of
HCT was 85% (including 75% complete remissions and 10% partial remissions)
(Fig. 4). The two-year probabilities of relapse, nonrelapse mortality, and
progression-free survival were 9%, 24%, and 60%, respectively.
Sorror et al. described outcomes in 64 patients with chronic lymphocytic
leukemia (median age 56 years) given HCT from HLA-matched related (n ¼ 44)
or unrelated (n ¼ 20) donors after conditioning consisting of 2 Gy TBI with
(n ¼ 53) or without (n ¼ 11) fludarabine (90 mg/m2) (51). Eighty-eight percent
of patients were refractory to fludarabine. With a median follow-up of
24 months, the overall response rate was 67% (including 50% with complete
remission). The two-year rates of nonrelapse mortality, overall, and progression-
free survivals were 22%, 60%, and 52%, respectively. Bulky lymphoadenopathy
(lymph node diameter 5 cm) independently predicted higher incidence of
relapse/progression (HR 3.8, p ¼ 0.009), while marrow infiltration with more
than 50% leukemic cells was associated with worse survival (HR 2.4, p ¼ 0.05).
These data, in agreement with those described in smaller series (52,53), show
that chronic lymphocytic leukemia is remarkably susceptible to GVT effects.
Multiple Myeloma
Crawley et al. reported data from 229 patients given allogeneic HCT after
various reduced-intensity conditioning in EBMT-affiliated centers (32). One
hundred and ninety-two patients received grafts from related donors and 37 from
unrelated donors. Overall, 25% and 48% of patients achieved complete or partial
remissions, respectively. The three-year probabilities of overall and progression-
free survivals were 41% and 21%, respectively. Adverse progression-free
survival was associated with alemtuzumab-containing conditioning (RR 1.8,
p ¼ 0.001) and chemoresistance prior to transplant (RR 2.4, p ¼ 0.0004),
suggesting that heavily pretreated patients and those with progressive disease did
not benefit from this approach. Chronic GVHD was associated with better
progression-free survival (p < 0.0001), while grades III to IV acute GVHD was
associated with a worse overall survival (p ¼ 0.0007) and did not decrease the
risk of relapse.
TANDEM AUTOLOGOUS/ALLOGENEIC HCT
To allow older patients with aggressive chemosensitive disease to benefit from
both high-dose chemotherapy and GVT effects, it has been proposed to first use
high-dose conditioning and autologous transplantation, which can be adminis-
tered with overall mortality rates of less than 5%, followed one to three months
later by allogeneic HCT using nonmyeloablative conditioning (tandem autolo-
gous/allogeneic HCT). This strategy, pioneered by Carella et al. in patients with
refractory lymphoma (54), was evaluated by Maloney et al. in 54 patients with
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multiple myeloma. Patients were first given autologous HCT after a cytor-
eductive dose of 200-mg/m2 melphalan; this was followed 40 to 229 (median 62)
days later by allogeneic HCT after 2 Gy TBI (55). Patients were 29 to 71
(median 52) years old, and 48% had refractory (35%) or relapsed (13%) disease.
Remarkably, the 100-day mortalities after autologous and allogeneic HCT were
2% each, contrasting with the high nonrelapse mortality (ranging from 20% to
50% (56) observed in patients with multiple myeloma given allogeneic HCT
after myeloablative conditioning. The two-year overall and progression-free
survivals were 78% and 55%, respectively.
CONCLUSIONS AND CLINICAL PERSPECTIVES
FOR THE NEXT FIVE YEARS
Reduced-intensity conditioning and nonmyeloablative regimens have allowed
engraftment of allogeneic hematopoietic cells and the development of GVT
effects. Antitumor responses have generally required extended periods of time,
with a median time of six months required before achievement of complete
remissions. In patients with slowly progressing diseases such as chronic myeloid
leukemia in first chronic phase, low-grade myelodysplastic syndrome, chronic
lymphocytic leukemia, or low-grade NHL, or with more aggressive diseases in
complete remission, nonmyeloablative conditioning may be sufficient to achieve
cure of the disease. A number of approaches are being explored for patients with
more aggressive diseases, such as acute leukemias, high-grade myelodysplastic
syndrome, multiple myeloma, or high-grade lymphomas, who are not in com-
plete remission.
A first approach is to combine nonmyeloablative HCT with ‘‘disease-
targeted’’ therapy, such as monoclonal antibodies or thalidomide. Khouri et al.
reported 17 patients with chronic lymphocytic leukemia given allogeneic grafts
from related donors after fludarabine (90 mg/m2) and cyclophosphamide
(2250 mg/m2) (53). Ten patients received rituximab in addition to chemotherapy.
The two-year overall survivals were 100% and 57%, in patients given or not
given rituximab Q4, respectively. We have been studying the administration of I-131
anti-CD45 monoclonal antibody followed by 2 Gy TBI and fludarabine to
condition patients with acute myeloid leukemia not in remission and patients
with advanced myelodysplastic syndrome (57). This approach has allowed
administration of 40 Gy to marrow and 56 Gy to spleen, with a relative sparing
of nonhematopoietic organs. Kroger et al. investigated the efficacy of thalido-
mide (100 mg) combined with DLI in 18 patients with multiple myeloma pro-
gressing after reduced-intensity HCT (58). The overall response rate was 67%,
including 22% complete remissions. No grades II to IV acute GVHD were seen,
while de novo limited chronic GVHD occurred in two patients (11%). The two-
year progression-free survival after DLI was 84%.
A second approach might consist of posttransplant infusion of donor-
specific cytotoxic T-cells directed against either tumor antigens (such as
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proteinase 3 or Wilms’ tumor-suppressor 1 in case of leukemia or patient par-
aprotein in case of multiple myeloma) or recipient minor histocompatibility
antigens expressed exclusively on hematopoietic cells (such as HA-1 and HA-2
minor histocompatibility antigens), potentially increasing antitumoral efficacy of
DLI with a low risk of inducing GVHD (59).
A number of prospective phase III studies aimed at better defining the role
of nonmyeloablative conditioning in patients with multiple myeloma (BMT-
CTN 01–02), lymphoma (BMT-CTN 02–02), or acute myeloid leukemia
(GOELAMS AML 2001, FHCRC-1992.00) are ongoing in the United States and
in Europe. Other randomized studies are focusing on comparing different
conditioning regimens (FHCRC-1813.00) or defining the best postgrafting
immunosuppression in the nonmyeloablative transplantation setting (FHCRC-
1938.00).
ACKNOWLEDGMENTS
We thank Bonnie Larson, Helen Crawford, and Sue Carbonneau for their help
with manuscript preparation.
REFERENCES
1. Storb R. Allogeneic hematopoietic stem cell transplantation: yesterday, today, and
tomorrow. Exp Hematol 2003; 31:1–10.
2. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host
disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;
300:1068–1073.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after
bone marrow transplantation. Blood 1990; 75:555–562.
4. Kolb HJ, Schmidt C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic
chimeras. Blood 2004; 103:767–776.
5. Barnes DWH, Corp MJ, Loutit JF, et al. Treatment of murine leukaemia with x-rays and
homologous bone marrow. Preliminary communication. Br Med J 1956; 2:626–627.
6. Collins RH Jr., Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140
patients with relapsed malignancy after allogeneic bone marrow transplantation.
J Clin Oncol 1997; 15:433–444.
7. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor
lymphocyte infusions after allogeneic hematopoietic cell transplantation following
nonmyeloablative conditioning. Blood 2004; 103:790–795.
8. Santos GW, Sensenbrenner LL, Burke PJ, et al. Marrow transplantation in man
following cyclophosphamide. Transplant Proc 1971; 3:400–404.
9. Appelbaum FR, Herzig GP, Ziegler JL, et al. Successful engraftment of cry-
opreserved autologous bone marrow in patients with malignant lymphoma. Blood
1978; 52:85–95.
10. Graw RG Jr., Lohrmann H-P, Bull MI, et al. Bone-marrow transplantation following
combination chemotherapy imunosuppression (B.A.C.T.) in patients with acute
leukemia. Transplant Proc 1974; 6:349–354.
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
Allogeneic Hematopoietic Cell Transplantation 555
[pradeepr][69-Standard][D:/informa_Publishing/DK0832_Kaspers_112039/z_pro-
duction/z_3B2_3D_files/978-0-8493-5083-2_CH0024_O.3d] [19/2/08/13:5:56]
[537–561]
11. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell trans-
plantation for the treatment of chronic myeloid leukemia in first chronic phase.
Blood 2003; 101:441–445 (comment in Blood 2003; 101(12):5084; author reply
5084–5085; PMID: 12788790).
12. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing prepa-
rative regimens: reduced-intensity conditioning for patients with hematologic
malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;
97:631–637.
13. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing
reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-
Hodgkin lymphoma. Blood 2004; 104:3865–3871.
14. Girgis M, Hallemeier C, Blum W, et al. Chimerism and clinical outcomes of 110
unrelated donor bone marrow transplants who underwent conditioning with low-
dose, single-exposure total body irradiation and cyclophosphamide. Blood 2005;
105:3035–3041.
15. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic
transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of
toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood
2001; 98:3595–3599.
16. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell trans-
plantation in older patients with hematologic malignancies: replacing high-dose
cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97 3390–3400.
17. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative
allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism
precedes alloimmune responses. Blood 1999; 94:3234–3241.
18. Storb RF, Champlin R, Riddell SR, et al. Non-myeloablative transplants for
malignant disease. In: Schechter GP, Broudy VC, Williams ME, eds. Hematology
2001: American Society of Hematology Education Program Book. Washington, DC:
The American Society of Hematology, 2001:375–391.
19. Baron F, Sandmaier BM. Current status of hematopoietic stem cell transplantation
after nonmyeloablative conditioning. Curr Opin Hematol 2005; 12:435–443.
20. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic
hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol
2005; 23:1993–2003.
21. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-
intensity conditioning regimens in the treatment of acute myeloid leukemia and high-
risk myelodysplastic syndrome: dose is relevant for long-term disease control after
allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:865–872.
22. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-
identical littermate dogs given sublethal total body irradiation before and pharmaco-
logical immunosuppression after marrow transplantation. Blood 1997; 89:3048–3054.
23. Kerbauy FR, Storb R, Hegenbart U, et al. Hematopoietic cell transplantation from
HLA-identical sibling donors after low-dose radiation-based conditioning for treat-
ment of CML. Leukemia 2005; 19:990–997.
24. Sandmaier BM, Maris M, Maloney DG, et al. Low-dose total body irradiation (TBI)
conditioning for hematopoietic cell transplants (HCT) from HLA-matched related
(MRD) and unrelated (URD) donors for patients with hematologic malignancies: a
five-year experience. Blood 2003; 102(pt 1):78a–79a (abstr 264).
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
556 Baron et al.
[pradeepr][69-Standard][D:/informa_Publishing/DK0832_Kaspers_112039/z_pro-
duction/z_3B2_3D_files/978-0-8493-5083-2_CH0024_O.3d] [19/2/08/13:5:56]
[537–561]
25. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor
hematopoietic cell transplantation after nonmyeloablative conditioning for patients
with hematologic malignancies. Blood 2003; 102:2021–2030.
26. Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism
by the use of a reduced-intensity conditioning regimen composed of fludarabine and
melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood
2003; 102:3829–3836.
27. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hema-
tologic malignancies given allogeneic hematopoietic cell transplantation after non-
myeloablative conditioning. Blood 2004; 104:2254–2262.
28. Sandmaier BM, Maloney DG, Maris MB, et al. Conversion of low donor chimerism
following nonmyeloablative conditioning for hematopoietic cell transplantation (HCT)
using pentostatin and donor lymphocyte infusion (DLI). Blood 2004; 104(pt 1):57a
(abstr 186).
29. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after non-
myeloablative versus conventional hematopoietic stem cell transplantation. Blood
2003; 102:756–762.
30. Sayer HG, Kro¨ger M, Beyer J, et al. Reduced intensity conditioning for allogeneic
hematopoietic stem cell transplantation in patients with acute myeloid leukemia:
disease status by marrow blasts is the strongest prognostic factor. Bone Marrow
Transplant 2003; 31:1089–1095.
31. Michallet AS, Furst S, Le QH, et al. Impact of chimaerism analysis and kinetics on
allogeneic haematopoietic stem cell transplantation outcome after conventional and
reduced-intensity conditioning regimens. Br J Haematol 2005; 128:676–689.
32. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic
transplantation for multiple myeloma: an analysis of prognostic factors from the
Chronic Leukemia Working Party of the EBMT. Blood 2005; 105:4532–4539.
33. Weissinger F, Sandmaier BM, Maloney DG, et al. Decreased transfusion require-
ments for patients receiving nonmyeloablative compared with conventional periph-
eral blood stem cell transplants from HLA-identical siblings. Blood 2001; 98:
3584–3588.
34. Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic
pneumonia syndrome after nonmyeloablative and conventional conditioning regi-
mens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102:
2777–2785.
35. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative con-
ditioning followed by allogeneic hematopoietic cell transplantation: a study of 193
patients. Blood 2004; 103:78–84.
36. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalo-
virus infections following nonmyeloablative compared with myeloablative alloge-
neic stem cell transplantation, a matched control study. Blood 2002; 99:1978–1985.
37. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and
fungal infections following nonmyeloablative compared with myeloablative allo-
geneic hematopoietic stem cell transplantation: a matched control study. Biol Blood
Marrow Transplant 2002; 8:512–520.
38. Parikh CR, Schrier RW, Storer B, et al. Comparison of ARF after myeloablative and
nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 2005; 45:
502–509.
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
Allogeneic Hematopoietic Cell Transplantation 557
[pradeepr][69-Standard][D:/informa_Publishing/DK0832_Kaspers_112039/z_pro-
duction/z_3B2_3D_files/978-0-8493-5083-2_CH0024_O.3d] [19/2/08/13:5:56]
[537–561]
39. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-
matched unrelated donor hematopoietic cell transplantation after nonmyeloablative
and myeloablative conditioning: influence of pretransplant comorbidities. Blood
2004; 104:961–968.
40. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with non-
myeloablative compared to myeloablative conditioning before hematopoietic cell
transplantation from HLA matched related donors. Blood 2004; 104:1550–1558.
41. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in
patients with acute myeloid leukemia in first remission: A randomized trial of two
irradiation regimens. Blood 1990; 76:1867–1871.
42. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in
patients with chronic myeloid leukemia in the chronic phase: A randomized trial of
two irradiation regimens. Blood 1991; 77:1660–1665.
43. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and
myeloablative allogeneic hematopoietic cell transplantation for patients older than
50 years of age. Blood 2005; 105:1810–1814.
44. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myeloge-
nous leukemia by low-dose, total-body, irradiation-based conditioning and hema-
topoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006;
24:444–453.
45. Mohty M, de Lavallade H, Ladaique P, et al. The role of reduced intensity con-
ditioning allogeneic stem cell transplantation in patients with acute myeloid leuke-
mia: a donor vs. no donor comparison. Leukemia 2005; 19:916–920.
46. Ho AYL, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic
stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia
with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC)
conditioning. Blood 2004; 104:1616–1623.
47. Baron F, Maris MB, Storer BE, et al. HLA-matched unrelated donor hematopoietic
cell transplantation after nonmyeloablative conditioning for patients with chronic
myeloid leukemia. Biol Blood Marrow Transplant 2005; 11:272–279.
48. Escalon MP, Champlin RE, Saliba RM, et al. Nonmyeloablative allogeneic hema-
topoietic transplantation: a promising salvage therapy for patients with non-Hodgkin’s
lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol
2004; 22:2419–2423.
49. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lym-
phoma predicts for a poor outcome following reduced-intensity allogeneic progenitor
cell transplantation: an analysis from the Lymphoma Working Party of the European
Group for Blood and Bone Marrow Transplantation. Blood 2002; 100:4310–4316.
50. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell trans-
plantation after fludarabine and 2 Gy total body irradiation for relapsed and
refractory mantle cell lymphoma. Blood 2004; 104:3535–3542.
51. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after
nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin
Oncol 2005; 23:3819–3829.
52. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia
effect in chronic lymphocytic leukemia after reduced-intensity conditioning and
allogeneic stem-cell transplantation: the Cooperative German Transplant Study
Group. J Clin Oncol 2003; 21:2747–2753.
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
558 Baron et al.
[pradeepr][69-Standard][D:/informa_Publishing/DK0832_Kaspers_112039/z_pro-
duction/z_3B2_3D_files/978-0-8493-5083-2_CH0024_O.3d] [19/2/08/13:5:56]
[537–561]
53. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell trans-
plantation for chronic lymphocytic leukemia: impact of rituximab on immunomo-
dulation and survival. Exp Hematol 2004; 32:28–35.
54. Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by non-
myeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood
hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease
and non-Hodgkin’s lymphoma. J Clin Oncol 2000; 18:3918–3924.
55. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative con-
ditioning following cytoreductive autografts for the treatment of patients with
multiple myeloma. Blood 2003; 102:3447–3454.
56. Bensinger WI. The current status of hematopoietic stem cell transplantation for
multiple myeloma. Clin Adv Hematol Oncol 2004; 2:700–706.
57. Pagel JM, Appelbaum FR, Sandmaier BM, et al. 131I-anti-CD45 antibody plus flu-
darabine, low-dose total body irradiation and peripheral blood stem cell infusion for
elderly patients with advanced acute myeloid leukemia (AML) or high-risk myelo-
dysplastic syndrome (MDS). Blood 2005; 106(pt 1):119a (abstr 397).
58. Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lym-
phocyte infusion as adoptive immunotherapy after allogeneic stem cell trans-
plantation in patients with multiple myeloma. Blood 2004; 104:3361–3363.
59. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia
effect. Nat Rev Cancer 2004; 4:371–380.
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
Allogeneic Hematopoietic Cell Transplantation 559
[pradeepr][69-Standard][D:/informa_Publishing/DK0832_Kaspers_112039/z_pro-
duction/z_3B2_3D_files/978-0-8493-5083-2_CH0024_O.3d] [19/2/08/13:5:56]
[537–561]
[pradeepr][69-Standard][D:/informa_Publishing/DK0832_Kaspers_112039/z_pro-
duction/z_3B2_3D_files/978-0-8493-5083-2_CH0024_O.3d] [19/2/08/13:5:56]
[537–561]
BOOK: DK0832_Kaspers CHAPTER 24
TO: CORRESPONDING AUTHOR
AUTHOR QUERIES - TO BE ANSWERED BY THE AUTHOR
The following queries have arisen during the typesetting of your
manuscript. Please answer these queries.
Q1 Page: 539 AU: Shortened Running Head title OK?
Q2 Page: 543 AU: Expansion for HLA OK?
Q3 Page: 547 AU: Expansion for CMV OK?
Q4 Page: 554 AU: Is insert of given in patients given or not
rituximab?
Q5 Page: 539 AU: Sources for Figures 1, 2, 3, and 4 OK as edited?
Chapter: 24 
Contributors : 1Authors: Frédéric Baron, 2Frederick R. Appelbaum and  
3Brenda M. sandmaier 
 
Affiliation  : 1Fred Hutchinson Cancer Research Center 
Address  : 1100 Fairview Ave N, D1-100; PO Box 19024; Seattle, WA 98109-1024 
Phone   :  
Fax :  
Email :  
 
Affiliation : 2Fred Hutchinson Cancer Research Center and the University of 
Washington, 
Address : 1100 Fairview Ave N, D1-100; PO Box 19024; Seattle, WA 98109-1024 
Phone :  
Fax :  
EmaiL                         : fappelba@fhcrc.org
 
Affiliation : 3Fred Hutchinson Cancer Research Center and the University of 
Washington, 
Address : 1100 Fairview Ave N, D1-100; PO Box 19024; Seattle, WA 98109-1024 
Phone : 206-667-4961 
Fax : 206-667-6124 
Email   : bsandmai@fhcrc.org
 
Contact author s : 3Brenda M. andmaier, 2Frederick R. Appelbaum 
